Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:3-(Cystein-S-yl)acetaminophen)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004194 AN006966 PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST004153 AN006894 Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model Feces Rat Shanghai Jiao Tong University LC-MS
ST003565 AN005857 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003179 AN005221 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003032 AN004969 Effects of Preanalytical Sample Collection and Handling on Comprehensive Metabolite Measurements in Human Urine Biospecimens Urine Human National Center for Advancing Translational Sciences Other
ST002820 AN004594 Evaluation of Novel Candidate Filtration Markers from a Global Metabolomics Discovery for Glomerular Filtration Rate Estimation (AASKG1) Blood Human Tufts Medical Center Other
ST002819 AN004590 Evaluation of Novel Candidate Filtration Markers from a Global Metabolomics Discovery for Glomerular Filtration Rate Estimation (MDRD) Blood Human Tufts Medical Center Other
ST002818 AN004586 Evaluation of Novel Candidate Filtration Markers from a Global Metabolomics Discovery for Glomerular Filtration Rate Estimation (ALTOLD) Blood Human Tufts Medical Center Other
ST002698 AN004372 Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites Infected Red Blood Cells Plasmodium berghei Malaria Peter Doherty Institute for Infection and Immunity LC-MS
ST002498 AN004654 Plasma Metabolomics Profiling of 580 Patients from the Weill Cornell Medicine Early Detection Research Network Prostate Cancer Cohort Blood Human Cancer Weill Cornell Medicine LC-MS
ST002104 AN003439 Chemoresistant Cancer Cell Lines are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations Cultured cells Human Cancer Future Industries Institute LC-MS
ST002089 AN003410 Plasma metabolomic signatures of COPD: A metabolomic severity score for airflow obstruction and emphysema. Blood Human COPD National Jewish Health LC-MS
ST002088 AN003406 Plasma Metabolomic signatures of COPD in a SPIROMICS cohort: A metabolomic severity score for airflow obstructions and emphysema Blood Human COPD National Jewish Health LC-MS
ST002020 AN003290 TIPs Metabolomics (urine) Urine Human Vanderbilt University Medical Center LC-MS
ST002017 AN003287 Multi-omic analysis of the microbiome and metabolome in healthy subjects (blood) Blood Human Vanderbilt University Medical Center LC-MS
ST002010 AN003276 Chemoresistant Ovarian Cancer Global Metabolomics Cultured cells Human Cancer University of South Australia LC-MS
ST001940 AN003155 Cognitive Behavioral Therapy for Irritable Bowel Syndrome Induces Bidirectional Alterations in the Brain-Gut-Microbiome Axis Associated with Gastrointestinal Symptom Improvement Feces Human Irritable bowel syndrome University of California, Los Angeles LC-MS
ST001940 AN003156 Cognitive Behavioral Therapy for Irritable Bowel Syndrome Induces Bidirectional Alterations in the Brain-Gut-Microbiome Axis Associated with Gastrointestinal Symptom Improvement Feces Human Irritable bowel syndrome University of California, Los Angeles LC-MS
ST001940 AN003157 Cognitive Behavioral Therapy for Irritable Bowel Syndrome Induces Bidirectional Alterations in the Brain-Gut-Microbiome Axis Associated with Gastrointestinal Symptom Improvement Feces Human Irritable bowel syndrome University of California, Los Angeles LC-MS
ST001940 AN003158 Cognitive Behavioral Therapy for Irritable Bowel Syndrome Induces Bidirectional Alterations in the Brain-Gut-Microbiome Axis Associated with Gastrointestinal Symptom Improvement Feces Human Irritable bowel syndrome University of California, Los Angeles LC-MS
ST001749 AN002848 REACH Metabolomics Study Blood Human Alzheimers disease University of Wisconsin-Madison LC-MS
ST001639 AN002681 Plasma Metabolomic signatures of COPD in a SPIROMICS cohort Blood Human COPD National Jewish Health LC-MS
ST001517 AN002518 Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria (part-III) Blood Human Malaria New York University Abu Dhabi LC-MS
ST001516 AN002515 Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria (part-II) Blood Human Malaria New York University Abu Dhabi LC-MS
ST001515 AN002511 A Metabolomic Signature of Glucagon Action in Healthy Individuals with Overweight/Obesity Humans Blood Human Obesity Translational Research Institute- AdventHealth Orlando LC-MS
ST001411 AN002361 Plasma metabolites of lipid metabolism associate with diabetic polyneuropathy in a cohort with screen-tested type 2 diabetes: ADDITION-Denmark Blood Human Obesity University of Michigan LC-MS
ST001404 AN002346 Ontogeny related changes in the pediatric liver metabolome (part-III) Liver Human Moffitt Cancer Center LC-MS
ST001403 AN002345 Ontogeny related changes in the pediatric liver metabolome (part-II) Liver Human Moffitt Cancer Center LC-MS
ST001402 AN002344 Ontogeny related changes in the pediatric liver metabolome Liver Human Moffitt Cancer Center LC-MS
ST001400 AN002340 Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria Blood Human Malaria New York University Abu Dhabi LC-MS
ST000975 AN001596 GC6-74 metabolomics of TB vs healthy (Part 2: Serum) Blood Human Tuberculosis Max Planck Institute for Infection Biology LC-MS
ST000974 AN001595 GC6-74 matabolomic of TB (Part 1: Plasma) Blood Human Tuberculosis Max Planck Institute for Infection Biology LC-MS
ST000899 AN001462 Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling Blood Human Inflammatory bowel disease Vanderbilt University Medical Center LC-MS
ST000106 AN000175 IWMS Study 1:Weight comparison of obese and lean patients Blood Human Obesity University of Michigan LC-MS
ST000105 AN000173 SCOR Metabolomics Blood Human University of Michigan LC-MS
ST000090 AN000143 Caloric Restriction vs drugs Blood Mouse University of Michigan LC-MS
ST000044 AN000068 Pilot experiment looking for the existence of certain molecules in pancreatic cancer cells Pancreas Human Cancer University of Michigan LC-MS
ST000042 AN000064 BALF Control vs ALI by RPLC-MS Lung Human University of Michigan LC-MS
ST000017 AN000034 Rat HCR/LCR Stamina Study Blood Rat University of Michigan LC-MS
ST000016 AN000033 NPM-ALK metabolic regulation Lymphoma cells Human University of Michigan LC-MS
ST000010 AN000025 Lung Cancer Cells 4 Lung Human Cancer University of Michigan LC-MS
ST000009 AN000023 Mixed meal tolerance Unspecified Human University of Michigan LC-MS
  logo